Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.6152
Dollar change
-0.0158
Percentage change
-2.50
%
Index- P/E- EPS (ttm)-3.01 Insider Own3.48% Shs Outstand16.67M Perf Week-11.49%
Market Cap10.26M Forward P/E- EPS next Y-3.48 Insider Trans0.00% Shs Float16.09M Perf Month-12.11%
Income-45.17M PEG- EPS next Q-0.65 Inst Own20.89% Short Float1.81% Perf Quarter45.44%
Sales11.87M P/S0.86 EPS this Y29.08% Inst Trans-15.67% Short Ratio0.29 Perf Half Y-66.75%
Book/sh-0.05 P/B- EPS next Y-33.33% ROA-77.05% Short Interest0.29M Perf Year-77.55%
Cash/sh2.45 P/C0.25 EPS next 5Y- ROE-426.46% 52W Range0.39 - 4.69 Perf YTD17.83%
Dividend Est.- P/FCF- EPS past 5Y14.32% ROI-190.93% 52W High-86.88% Beta1.45
Dividend TTM- Quick Ratio2.11 Sales past 5Y-25.00% Gross Margin- 52W Low56.94% ATR (14)0.17
Dividend Ex-Date- Current Ratio2.11 EPS Y/Y TTM8.52% Oper. Margin-372.82% RSI (14)47.85 Volatility11.96% 36.51%
Employees34 Debt/Eq- Sales Y/Y TTM- Profit Margin-380.49% Recom1.00 Target Price9.50
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q27.95% Payout- Rel Volume0.47 Prev Close0.63
Sales Surprise- EPS Surprise28.21% Sales Q/Q- EarningsOct 27 BMO Avg Volume1.00M Price0.62
SMA20-15.61% SMA50-1.36% SMA200-58.22% Trades Volume470,746 Change-2.50%
Date Action Analyst Rating Change Price Target Change
Jul-09-21Initiated Jefferies Buy $8
Jan-14-19Reiterated H.C. Wainwright Buy $12 → $8.50
Mar-27-24 08:07AM
Mar-12-24 02:34PM
09:58AM
Mar-11-24 07:00AM
Mar-06-24 07:00AM
07:00AM Loading…
Feb-29-24 07:00AM
Jan-08-24 06:45AM
Jan-02-24 07:00AM
Dec-12-23 07:00AM
Nov-20-23 07:00AM
Nov-03-23 07:00AM
Oct-27-23 08:00AM
Oct-24-23 08:00AM
Oct-18-23 07:00AM
Oct-13-23 09:30AM
07:00AM Loading…
Sep-22-23 07:00AM
Sep-07-23 07:00AM
Aug-11-23 07:00AM
Jul-07-23 10:42AM
Jul-06-23 11:09AM
07:55AM
Jul-05-23 04:30PM
Jun-23-23 07:00AM
Jun-22-23 07:30AM
Jun-01-23 07:00AM
May-18-23 07:00AM
May-15-23 07:00AM
Apr-28-23 07:00AM
Apr-27-23 09:40AM
Apr-24-23 07:00AM
09:40AM Loading…
Apr-05-23 09:40AM
Mar-28-23 07:00AM
Mar-24-23 07:00AM
Mar-22-23 07:00AM
Mar-20-23 09:40AM
Mar-14-23 07:00AM
Mar-13-23 07:54AM
Mar-10-23 07:00AM
Mar-09-23 09:55AM
Mar-08-23 07:00AM
Mar-02-23 09:40AM
Feb-28-23 07:00AM
Feb-24-23 06:00AM
05:59AM
Jan-03-23 07:00AM
Dec-22-22 11:34AM
Dec-19-22 01:53PM
Dec-16-22 07:00AM
Dec-15-22 07:00AM
Nov-21-22 07:00AM
Nov-10-22 02:17PM
Nov-09-22 10:17AM
Nov-08-22 07:00AM
Oct-28-22 07:00AM
Sep-28-22 10:24AM
07:00AM
Sep-14-22 11:05AM
07:15AM
Sep-13-22 07:00AM
Sep-07-22 06:00AM
Sep-02-22 07:00AM
Aug-25-22 07:03AM
Aug-22-22 07:00AM
Aug-12-22 07:00AM
Aug-11-22 07:00AM
Jun-07-22 07:00AM
Jun-06-22 07:00AM
May-31-22 07:00AM
May-20-22 07:00AM
May-18-22 07:00AM
May-10-22 07:00AM
Apr-27-22 07:00AM
Apr-06-22 07:00AM
Apr-01-22 05:00PM
Mar-28-22 07:00AM
Mar-25-22 07:00AM
Mar-18-22 07:00AM
Mar-15-22 07:00AM
Jan-21-22 10:55AM
Jan-20-22 04:05PM
Jan-18-22 08:06AM
Jan-11-22 07:00AM
Jan-06-22 07:00AM
Dec-06-21 07:00AM
Nov-22-21 07:00AM
Nov-10-21 07:00AM
Oct-26-21 07:00AM
Oct-22-21 07:00AM
Oct-18-21 07:00AM
Oct-14-21 07:00AM
Sep-28-21 10:11AM
Sep-27-21 02:30PM
12:11PM
10:15AM
06:00AM
Sep-22-21 07:00AM
Sep-21-21 07:00AM
Sep-13-21 08:38AM
Sep-09-21 07:00AM
Aug-06-21 07:00AM
Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.